Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. plans to invest 1.4985 billion RMB as a limited partner in the establishment of the second phase of the Guangzhou Traditional Chinese Medicine Fund, representing 99.90% of the total subscription amount [1][2][3] Summary by Sections Investment Overview - The total scale of the second phase of the Guangzhou Traditional Chinese Medicine Fund is 1.5 billion RMB, with the company contributing 1.4985 billion RMB [2][3] - The fund manager is Guangzhou Guangyao Capital Private Fund Management Co., Ltd., a subsidiary of the company's controlling shareholder, Guangzhou Pharmaceutical Group [1][4] Transaction Details - The investment does not constitute a major asset restructuring as defined by relevant regulations, and does not require shareholder approval [2][3] - The company has not exceeded 5% of its latest audited net assets in transactions with the same related party over the past 12 months, thus no shareholder meeting is required [2][4] Fund Structure and Management - The fund will focus on equity investments in the biopharmaceutical sector, aiming to generate investment returns [4][8] - The fund has a lifespan of 13 years, with a 10-year investment period and a 3-year exit period [4][6] Financial and Operational Impact - The investment is expected to enhance the company's capital operation capabilities and accelerate external investment efforts, contributing to the company's transformation and rapid development in the biopharmaceutical sector [8] - The investment will not significantly impact the company's current financial status or normal operations [8] Governance and Decision-Making - An investment decision-making committee will be established, consisting of three members, with voting rights equally distributed [6][7] - The company’s independent directors have approved the investment, affirming its fairness and alignment with the company's strategic goals [7][8]

证券代码：600332 证券简称：白云山 公告编号：2025－055 广州白云山医药集团股份有限公司 关于子公司中期票据和超短期融资券获准注册的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（"本公司"）第九届董事会第八 次会议和 2023 年年度股东大会审议通过了《关于本公司控股子公司广州 医药股份有限公司申请注册中期票据及超短期融资券的议案》，同意提请 股东大会授权本公司控股子公司广州医药股份有限公司（"广州医药"） 在中国银行间交易商协会申请注册发行总额度不超过人民币 16 亿元的中 期票据及总额度不超过人民币 20 亿元的超短期融资券，在注册有效期内 分期择机发行事宜。具体内容详见本公司日期为 2024 年 3 月 15 日、2024 年 5 月 30 日的公告。 广州医药于今日收到中国银行间市场交易商协会（"交易商协会"） 出具的《接受注册通知书》（"通知书"）（中市协注【2025】MTN687 号、中市协注【2025】SCP195 号），交易商协会决定接受广州医药中期 票据、超 ...

证券代码：600332 证券简称：白云山 公告编号：2025－054 广州白云山医药集团股份有限公司 关于参与投资设立股权投资基金暨关联交易的公告 ●投资标的及交易内容：广州白云山医药集团股份有限公司（"本 公司"）拟作为有限合伙人以自有资金出资14.985亿元（人民币，下 同）参与设立广州广药基金二期股权投资合伙企业（有限合伙）（拟 定名，具体以企业登记机构核准的名称为准，"广药基金二期"、"基 金"），占广药基金二期认缴出资总额的99.90%。 ●广药基金二期的管理人为广州广药资本私募基金管理有限公 司（"广药资本"），广药资本是本公司控股股东广州医药集团有限 公司（"广药集团"）持股80%的控股子公司。广药资本作为执行事 务合伙人、基金管理人和普通合伙人认缴出资150.00万元。本公司副 董事长程宁女士担任广药资本的董事长。因此，本公司本次认购广药 基金二期份额构成关联交易。 ●本事项已经本公司第九届董事会第二十七次会议审议通过。本 公司本次认购基金份额不构成《上市公司重大资产重组管理办法》规 定的重大资产重组。 ●截至本公告披露日，过去12个月内本公司与同一关联人进行的 交易，扣除可以豁免提交股东大会 ...

Core Viewpoint - Baiyunshan (600332) plans to invest 1.498 billion yuan as a limited partner in the second phase of the Guangzhou Pharmaceutical Fund, representing 99.90% of the total committed capital of 1.5 billion yuan [1] Group 1: Investment Details - The total scale of the second phase of the Guangzhou Pharmaceutical Fund is 1.5 billion yuan, managed by Guangzhou Guangyao Capital Private Fund Management Co., Ltd. [1] - Baiyunshan's investment constitutes a related party transaction but does not qualify as a major asset restructuring [1] Group 2: Financial Indicators of Guangyao Capital - As of June 30, 2025, Guangyao Capital reported total assets of 27.9588 million yuan, net assets of 19.4081 million yuan, operating income of 10.5777 million yuan, and net profit of 3.6221 million yuan [1] - For the year ending December 31, 2024, total assets were 30.9367 million yuan, net assets were 15.786 million yuan, operating income was 15.7202 million yuan, and net profit was 5.2937 million yuan [1]

在区域分布上，上榜粤企主要集中于深圳（36家）、广州（21家）、佛山（8家）等城市，其中广深包 揽了上榜粤企前10名中的9席。 | 排名 ^ | 公司名称 ○ (中文) | 营业收入 ℃ (百万美元) | 利润 ℃ (百万美 | 关键 数据 | | --- | --- | --- | --- | --- | | | | | 元) | | | 111 | 怡和集团 | 35,779 | -468 | + | | 112 | 铜陵有色金属集团控股有限公司 | 35,773.5 | 175.2 | + | | 113 | 蜀道投资集团有限责任公司 | 35,732.8 | 533.9 | + | | | 114 广州市建筑集团有限公司 | 35,676 | 108.9 | + | | 115 | 广州医药集团有限公司 | 35,164.1 | 316.5 | + | | 116 | 碧桂园控股有限公司 | 35,128.6 | -4,563.5 | + | | 117 | 和硕联合科技股份有限公司 | 35,058.2 | 2528 | - | 据榜单发布方《财富》杂志统计，2025年上榜的500家中国公司，上榜门 ...

Core Themes - The third China International Supply Chain Promotion Expo (Chain Expo) was held in Beijing, focusing on six major chains including advanced manufacturing, clean energy, smart automotive, digital technology, health living, and green agriculture [1] - Over 650 enterprises and institutions from 75 countries and regions participated, with foreign exhibitors accounting for 35% [1] Company Highlights - Yiling Pharmaceutical showcased its achievements in promoting high-quality development in traditional Chinese medicine (TCM) through solidifying the industrial chain, activating the innovation chain, and extending the health chain [3] - Yiling Pharmaceutical emphasized strict quality control of Chinese medicinal materials, establishing over 60 cultivation bases across the country, which also helps local farmers increase their income [4] - The company presented patented new drugs and innovative products in the health sector, including the Ba Zi Bu Shen capsule, which focuses on anti-aging applications [4] - Yiling Pharmaceutical aims to enhance the internationalization of TCM, with a product distribution map covering over 50 countries and regions [5] Industry Innovations - Guangzhou Pharmaceutical Group, the first TCM company to enter the Fortune Global 500, demonstrated its innovative practices in the TCM supply chain through a digital ecosystem, research innovation, and smart logistics [6] - The group has established nearly 90 standardized planting bases and has implemented blockchain technology for traceability and quality control, achieving a 148% increase in production capacity and a 289% increase in efficiency [6] - Sanofi highlighted its 30 years of localization in China, showcasing its high-quality manufacturing capabilities and a comprehensive immunization service chain [7][8] - GE Healthcare presented its latest high-end medical equipment and announced the establishment of a green supply chain innovation ecosystem alliance to promote sustainable practices in the medical device industry [9] - Steady Medical emphasized its commitment to reducing environmental pollution and introduced a new series of medical beauty products aimed at protecting public health [10]

证券代码：600332 证券简称：白云山 公告编号：2025-053 广州白云山医药集团股份有限公司 关于子公司获得药品补充申请批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"）子 公司广州白云山陈李济药厂有限公司（以下简称"陈李济药厂"）收到国 家药品监督管理局（以下简称"国家药监局"）签发的《药品补充申请批 准通知书》。现将有关情况公告如下： 一、药品的基本情况 生产企业：（1）名称：广州白云山陈李济药厂有限公司；（2）地址： 广州市海珠区广州大道南 1688 号 申请内容：变更药品规格 1 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准本品变更药品规格的补充申请，同意 增加小蜜丸规格，规格：每 40 丸重 10g（每 1g 相当于饮片 0.52g），有 效期：24 个月。 药品通用名称：千金保孕丸 剂型：丸剂（小蜜丸） 通知书编号：2025B01053 受理号：CYZB2401460 药品注册标准编号：Y ...

白云山（600332）公告，子公司陈李济药厂收到国家药监局签发的《药品补充申请批准通知书》。药品 通用名称为千金保孕丸，剂型为丸剂(小蜜丸)，通知书编号为2025B01053，受理号为CYZB2401460，药 品注册标准编号为YBZ00162025。原药品批准文号为国药准字Z44022637。申请内容为变更药品规格， 审批结论为批准本品变更药品规格的补充申请，同意增加小蜜丸规格，规格：每40丸重10g(每1g相当于 饮片0.52g)，有效期：24个月。 ...

Group 1 - Haitong Development reported a net profit of 86.87 million yuan for the first half of 2025, a year-on-year decrease of 64.14% [1] - Haitong Development achieved an operating income of 1.8 billion yuan, a year-on-year increase of 6.74% [1] - Crystal Integrated expects a net profit increase of 39.04% to 108.55% for the first half of 2025, with projected revenue between 5.07 billion yuan and 5.32 billion yuan [1] Group 2 - Aerospace Universe anticipates a net profit increase of 50.59% for the first half of 2025, with a projected net profit of 34.38 million yuan [2] - Aerospace Universe's net profit excluding non-recurring gains is expected to grow by 94.90% [2] Group 3 - Guodian Power reported a total power generation of 206.03 billion kWh for the first half of 2025, a year-on-year decrease of 3.61% [3] - The company's market-based transaction electricity accounted for 91.84% of the total electricity sold [3] Group 4 - Shanghai Pharmaceuticals announced that its tranexamic acid injection has passed the consistency evaluation for generic drugs [5] - The drug is primarily used for treating various bleeding disorders [5] Group 5 - Sanyou Chemical received approval to issue up to 900 million yuan in technology innovation corporate bonds [7] - The bond issuance is valid for 24 months from the date of approval [7] Group 6 - Baiyuntian's BAT4406F injection drug has received approval for clinical trials for additional indications [9] - The drug is a next-generation fully human anti-CD20 antibody [9] Group 7 - Huason Pharmaceutical received three drug re-registration approval notices [10] - The approved drugs include Ganji Bingmei tablets and other formulations [10] Group 8 - Shanying International plans to establish the Zhiyuan Fund with a total scale of 100 million yuan [13] - The fund will primarily invest in product companies related to industrial scenarios [13] Group 9 - Yiqiu Resources announced the sale of two properties in Malaysia for a total of approximately 3.67 million yuan [15] - The sale is part of the company's asset management strategy [15] Group 10 - Guizhou Bailing plans to apply for loans totaling no more than 920 million yuan from multiple banks [16] - The loans will be used to replace maturing loans and supplement working capital [16] Group 11 - Samsung Medical's subsidiary won a transformer procurement contract in Brazil worth approximately 341 million yuan [16] - The contract is part of the company's expansion into international markets [16] Group 12 - Changying Tong expects a net profit increase of 72.12% to 110.33% for the first half of 2025 [17] - The projected revenue is between 173 million yuan and 211 million yuan [17] Group 13 - Canqin Technology anticipates a net profit increase of 50.14% to 61.85% for the first half of 2025 [17] - The expected revenue is between 286 million yuan and 290 million yuan [17] Group 14 - Daya Shengxiang signed a lease agreement with an annual rent of 17 million yuan for a production facility [18] - The lease term is for 3 years and 4 months, including a 4-month rent-free period [18] Group 15 - Zhongzai Zihuan announced the resignation of its general manager due to work adjustments [20] - The company will appoint an interim general manager while searching for a permanent replacement [20] Group 16 - Fuwei Co. received a project notification from a well-known luxury brand for seat development [22] - The total sales amount for the project is expected to reach 4.9 billion yuan [22] Group 17 - Meili Technology's application for convertible bonds has been accepted by the Shenzhen Stock Exchange [26] - The issuance is subject to further approval from regulatory authorities [26] Group 18 - Jinzhik Technology announced a stock suspension due to potential control changes [27] - The suspension is expected to last no more than two trading days [27] Group 19 - Zhongtian Technology plans to distribute a cash dividend of 3 yuan per 10 shares [28] - The dividend distribution date is set for July 25, 2025 [28] Group 20 - Huahai Chengke plans to distribute a cash dividend of 0.2002 yuan per share [30] - The dividend distribution date is set for July 29, 2025 [30] Group 21 - Dasheng Intelligent won a smart transportation project contract worth 122 million yuan [31] - The project involves comprehensive monitoring systems for urban rail transit [31] Group 22 - Dongyue Silicon reported a fire incident affecting production operations [32] - The fire has been controlled, but the extent of damage is still being assessed [32] Group 23 - Shaanxi Guotou A reported a net profit of 726 million yuan for the first half of 2025, a year-on-year increase of 5.74% [35] - The company's operating income decreased by 2.95% [35] Group 24 - Yibo Technology announced a plan to reduce shareholding by up to 3% [37] - The reduction is due to the shareholder's funding needs [37] Group 25 - Xiling Information announced a stock suspension due to potential control changes [39] - The suspension is expected to last no more than two trading days [39] Group 26 - Tianli Lithium Energy plans to reduce shareholding by 4.55% through block trading [40] - The reduction is due to the fund's operational timeline nearing its end [40] Group 27 - Sihui Fushi announced plans for a combined shareholding reduction of up to 3% [42] - The reduction is due to the shareholders' personal funding needs [42] Group 28 - Jinma Leisure announced a plan for a combined shareholding reduction of up to 4.83% [44] - The reduction is due to personal funding needs of the controlling shareholder and executives [44] Group 29 - *ST Zitian's stock may be terminated due to financial reporting issues [46] - The company is under regulatory scrutiny for failing to rectify its financial statements [46]

证券代码：600332 证券简称：白云山 公告编号：2025－052 广州白云山医药集团股份有限公司 关于分公司收到药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 分公司广州白云山医药集团股份有限公司白云山制药总厂（以下简称 "白云山制药总厂"）收到国家药品监督管理局核准签发关于盐酸曲 美他嗪缓释片（35mg）的《药品注册证书》。现将相关情况公告如下： 一、药品的基本情况 药品通用名称：盐酸曲美他嗪缓释片 剂型：片剂 规格：35mg 注册分类：化学药品 4 类 证书编号：2025S02152 药品注册标准编号：YBH16172025 上市许可持有人：（1）名称：广州白云山医药集团股份有限公 司白云山制药总厂；（2）地址：广州市白云区同和街云祥路 88 号 生产企业：（1）名称：广州白云山医药集团股份有限公司白云 山制药总厂；（2）地址：广州市白云区同和街云祥路 88 号 受理号：CYHS2400195 药品批准文号：国药准字 H20254831 药 ...